CRI Logo
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Types
    • Cancer Types
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact
Donate

Immune to Cancer: The CRI Blog

  • AACR17 Update: Checkpoints, Vaccines, and the Power of Prediction

    Day 3 at AACR17 highlighted the importance of immune memory and personalized approaches…

    April 3, 2017| Arthur N. Brodsky, PhD
  • AACR17 Update: CAR T Cells, Regulatory T Cells, and the Future of Immunotherapy

    Day two addressed several strategies to improve immunotherapy’s precision and effectiveness

    April 2, 2017| Arthur N. Brodsky, PhD
  • AACR17 Update: Taking Immunotherapy to the Next Level

    After cancer immunotherapy’s initial successes, new challenges are being confronted

    April 1, 2017| Arthur N. Brodsky, PhD
  • AACR17: Immunotherapy’s Impact on the Future of Cancer Treatment

    Dozens of CRI scientists to highlight the latest immunotherapy breakthroughs during five-day conference in nation’s capital.

    March 31, 2017| Arthur N. Brodsky, PhD
  • CICON16: The Future of Cancer Immunotherapy

    CICON16 ended by focusing on emerging treatments and technologies in cancer immunotherapy.

    October 5, 2016| Arthur N. Brodsky, PhD
  • CICON '16

    CICON16: The Power of Combinations

    Targeting tumors from multiple angles improves our odds of success.

    September 30, 2016| Arthur N. Brodsky, PhD
  • CICON16: Bacteria and Cancer Immunity

    New research shows that bacteria within us can influence both the development of cancer and the immune…

    September 28, 2016| Arthur N. Brodsky, PhD
  • CICON16: Corrupted by Cancer

    Day 2 of CICON16 explored strategies to overcome challenges within the tumor microenvironment.

    September 27, 2016| Arthur N. Brodsky, PhD
  • CICON16: Beyond PD-1 and CTLA-4: The New Checkpoints

    The latest advances in using new checkpoint drugs to target LAG-3, Nrp1, IL-35R, CD36, and mitochondrial metabolism.

    September 26, 2016| Arthur N. Brodsky, PhD
Previous Page
1 … 7 8 9 10 11 … 15
Next Page

Cancer Research Institute
29 Broadway, Floor 4

New York, NY  10006-3111

Facebook Icon
X icon
YouTube icon
LinkedIn icon
Instagram icon
Threads icon
  • About
    • Impact
    • History
    • Team
    • Careers
    • Blog
    • Media Room
  • What is Immunotherapy?
    • Immunotherapy Basics
    • Treatment Type
    • Cancer Type
    • Side Effects
  • Patient Support
    • Patient Resources
    • Clinical Trials
    • Immunotherapy Stories
    • Connect with ImmunoAdvocates
  • Grants & Research Programs
    • Apply for Grants
    • Research Programs
    • Clinical Programs
    • Data Programs
    • CRI Funded Scientists
  • Get Involved
    • Donate
    • Ways to give
    • Fundraise
    • Events
    • Partnership
    • Contact

Uniting for a World Immune to Cancer

  • Accessibility Statement
  • Privacy Policy
  • Terms & Conditions
  • Site Map

*Immunotherapy results may vary from patient to patient.

©2025, Cancer Research Institute